MBX P. Kent Hawryluk buys $535K worth of shares
Feb 06, 2025, 5:33 AM
-1.44%
What does MBX do
MBX Biosciences, a clinical-stage biopharmaceutical company based in Carmel, Indiana, focuses on precision peptide therapies for endocrine and metabolic disorders and went public on September 13, 2024. Its product candidates include MBX 2109, MBX 1416, and MBX 4291, targeting various hormone-related conditions.
P. Kent Hawryluk bought 50,000 shares of MBX on 4 February at $10.69 per share, worth a total of $535K. They now own 448,277 MBX shares, or a 13% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.